Recently, p73, a protein with structural and functional similarities to p53, an extensively studied tumor suppressor gene, has been cloned. After being mapped to the chromosomal region 1p35-1p36, it has been postulated to act as a tumor suppressor gene, too, as this region is altered in several human malignancies. Deletions of the short arm of chromosome 1 have frequently been described in multiple myeloma (MM) whereas structural abnormalities of the 17p13 region including p53 are rare events in this disease. Since it has been proposed that especially neoplasias lacking p53 alterations might show a loss of heterozygosity at 1p35-1p36, we studied the frequency of p53 and p73 deletions in bone marrow mononuclear cells of 68 patients with MM, two patients with monoclonal gammopathy of undetermined significance and four patients with plasma cell leukemia. Dual-color fluorescence in situ hybridization (FISH) for p53 and p73 was performed using commercially available DNA probes for 17p13.3 and the microsatellite marker D1Z2, respectively. Centromeric DNA probes served to distinguish gene deletions from whole chromosome losses. In contrast to recently published FISH results, we only detected heterozygous p53 deletions in eight out of the 74 patients, three of them showing a monosomy 17. Heterozygous deletions of the D1Z2 region at 1p36 were found in six cases with one patient having a monosomy 1. Neither homozygous deletions of either chromosomal region nor nullisomies 1 or 17 could be detected. These results argue against a major role of p73 deletions in MM. As MM patients with 1p structural abnormalities have a significantly poorer survival rate than those with normal karyotypes, the role of other putative tumor suppressor genes located at the chromosomal region 1p36 in the pathogenesis of MM has to be determined.
Introduction
The tumor suppressor gene p53, located at the chromosomal region 17p13, is known to be deleted in a variety of human neoplasms.
1 p53 has been implicated in the control of cellular proliferation, differentiation and apoptosis, and its ability to inhibit cell growth is due, at least in part, to transcriptional activation of target genes such as that encoding the cell cycle inhibitor p21 WAF1/Cip1 leading to G 1 /S-phase arrest and apoptosis. In hematological malignancies, p53 mutations occur at a lower frequency compared with solid tumors, but when present they appear to be prognostically relevant in patients with aggressive or advanced stages of disease, as it has been found in non-Hodgkin's lymphomas, myelodysplastic syndromes, acute myeloid leukemia and blastic crisis of chronic myelogenous leukemia. [2] [3] [4] [5] Recently, several proteins showing functional or structural similarities to p53 have been described, suggesting that p53 belongs to a gene family whose function still remains to be exactly defined. Several isoforms of the human homolog of the rat Ket gene, named p51, p63, p73, p73L and p40, includ- ing various splicing variants have been identified as putative p53 family members. [6] [7] [8] [9] [10] [11] [12] Mutations or deletions of genes encoding these proteins have rarely been found in human cancers or hematological malignancies so far. 8, [13] [14] [15] [16] [17] [18] [19] [20] [21] After being mapped to the chromosomal region 1p35-1p36, p73 has been postulated to act as a tumor suppressor gene, as this region was shown to be deleted in several human malignancies including neuroblastoma, pheochromocytoma, oligodendroglioma, melanoma, merkel cell cancer, germ cell cancer, breast cancer, ovarian cancer, liver cancer and colon cancer as well as in some precancerous lesions like colorectal adenomas. 20, [22] [23] [24] [25] [26] Recently published preliminary data discussed the role of p73 in hematologic neoplasias, 27, 28 as well as in renal cell carcinoma 29 and lung cancer. 23 Although initial analysis of neuroblastoma cell lines failed to reveal p73 mutations, Kaghad et al 6 suggested that monoallelic transcription of p73 and absence of protein expression in neuroblastomas with hemizygous 1p36 deletions were consistent with involvement in tumor development supporting the notion that p73 might act as a tumor suppressor gene in malignancies with 1p36 deletions. However, the chromosomal region 1p36 is thought to harbor at least two tumor-suppressor genes. p73 has been mapped to the distal border of the minimal consensus region of neuroblastoma, 1p36.2-3, limited by the microsatellites D1Z2 and D1S47. 31 Multiple myeloma (MM) is a B cell neoplasia characterized by the proliferation of a malignant plasma cell population. Due to a low percentage of plasma cell mitoses in comparison to normal hematopoietic progenitor cells, numeric or structural chromosomal abnormalities could only be detected in 30-50% of patients by conventional cytogenetic studies, [32] [33] [34] whereas flow cytometry, 35 comparative genomic hybridization, 36 measurement of DNA content 37, 38 and interphase fluorescence in situ hybridization (FISH) 35 revealed an up to 90% incidence of aneuploidy in MM patients. 36, 39, 40 Among the structural chromosomal aberrations found, abnormalities of chromosome 1p are known to occur frequently in MM patients 41, 42 whereas structural changes of the short arm of chromosome 17 have been described to a much smaller extent. Also, in this malignancy p53 mutations are very rare at the time of diagnosis and even in patients with advanced or aggressive forms of MM, p53 mutations were found in no more than 20% of patients. 43 Since it has been proposed that especially neoplasias lacking p53 alterations might show a loss of heterozygosity at 1p35-1p36, 6 we studied the frequency of deletions of p53 and its proposed new homolog p73 at 1p36 in bone marrow mononuclear cells of MM patients. Additionally, since various structural and numerical chromosome aberrations in MM like partial or complete deletions of chromosome 13 and 11q abnormalities 44 or, as recently concluded, p53 deletions 45 are predictive for a worse prognosis, and since chromosomal abnormalities of 1p have been found to be associated with shorter event-free and overall survival, 44 we sought to investigate if possible 1p36 deletions were correlated with advanced disease.
Materials and methods

Patients
Heparinized bone marrow samples as well as bone marrow smears were obtained from 68 patients with MM and two with monoclonal gammopathy of undetermined significance (MGUS). Peripheral blood samples from four patients with plasma cell leukemia (PCL) were also included. Bone marrow and peripheral blood samples were taken after informed consent according to the Declaration of Helsinki. Peripheral blood samples from eight normal individuals served as controls for determination of cut-off values.
Determination of plasma cell content
Plasma cell contents of the bone marrow and peripheral blood samples were estimated either by conventional May-Grü nwald-Giemsa staining or by flow cytometry after staining with CD38 and CD138 antibodies using the CycloScope kit (Medac, Hamburg, Germany) according to the manufacturer's instructions.
Fluorescence in situ hybridization (FISH)
Heparinized bone marrow samples or peripheral blood samples were subjected to Ficoll gradient centrifugation (density 1.077 g/ml, Pharmacia, Freiburg, Germany). Buffy coats were washed once with phosphate-buffered saline (PBS). Part of the specimen was used for morphological analysis of May-Grü nwald-Giemsa-stained slides or flow cytometry; the remainder of the cell suspension was brought on to slides, fixed in methanol/acetic acid 3:1 and stored at −70°C. Dualcolor FISH was performed following standard protocols with slight modifications. 46 Briefly, slides were fixed in methanol for 10 min, digested in 0.01 N HCl containing 3-5 mg/100 ml pepsin (Serva, Heidelberg, Germany), washed twice in PBS and fixed with 1% paraformaldehyde (Sigma, Deisenhofen, Germany) and 5 mM MgCl 2 (Merck, Darmstadt, Germany) in PBS. After dehydration in 70%, 90% and 100% ethanol for 10 min each, slides were denatured in 70% formamide (Merck) in 2 × SSC for 2 min at 72°C. After incubation in 100 mM ice-cold CaCl 2 and a second dehydration step, hybridization was performed for 12 to 16 h. Commercially available DNA probes for p53 (Vysis, Stuttgart, Germany) and p73/1p36.3 (D1Z2) (Oncor, Heidelberg, Germany) were used with centromeric DNA probes for chromosomes 17 D17Z1 (Vysis) and 1 (D1Z5) (Oncor) as controls. 47 Hybridization with Oncor probes was performed as described previously. Vysis DNA probes were treated following the instructions of the manufacturer. Slides were counterstained in Vectashield (Vector, Burlingame, CA, USA) anti-fading medium containing 4,6-diamino-2-phenylindole-dihydrochloride (DAPI) 1 g/ml. Evaluation was performed by analyzing at least 200 interphase nuclei per sample using fluorescence microscopy. Means and standard deviations (s.d.) of the percentages of nuclei with 0, 1, and 2 domain signals were calculated for the control specimens. A cut-off value for a decision of mono-or nullisomy and deletions was based on the percentage of cells with zero and one signal, respectively, being greater than the mean percentage ± 3 s.d. of the controls.
Results
Clinical features
Bone marrow samples from 68 MM and two MGUS patients as well as blood samples from four patients with PCL were analyzed. The median age of the patients was 56 years (range 36 to 77 years). According to the staging system of Durie and Salmon, 48 54 out of the 68 MM patients had stage III myeloma whereas only five and nine patients could be classified as suffering from stage I or stage II myeloma, respectively. Female and male patients were equally distributed among the groups. M-protein gradients revealed a percentage of 62% (46/74) IgG, 18% (13/74) IgA, 16% (12/74) light-chains only, 1% (1/74) IgD and 3% (2/74) nonsecretory myeloma, MGUS, or PCL, thus reflecting currently known distributions. Sixteen out of the 74 patients were studied at initial diagnosis whereas 58 patients had been receiving chemotherapy and/or radiotherapy before. Median time from diagnosis was 1.5 years (0.0-22.8 years) for all patients vs 2.0 (0.2-22.8) years for patients under therapy (Table 1) .
Structural and numerical chromosomal abnormalities of chromosomes 1 and 17 as detected by FISH
Interphase FISH revealed a monoallelic deletion of the 1p36 region in six of 61 evaluable patients (9.8%), one of them showing a monosomy 1. No homozygous 1p36 deletions could be detected. Eight out of 61 patients (13.1%) had a monoallelic p53 deletion, three of them with a monosomy 17 in a significant number of cells. Only one of the patients had both, a 1p36 as well as a p53 deletion (Table 2) . Cut-off values, determined by analysis of peripheral blood samples from eight normal individuals for each DNA probe, were 9.6% for 1p36 deletions (mean 3.6%, s.d. 2.0%), 5.9% for monosomy 1 (mean 1.4%, s.d. 1.5%), 10.5% for 17p13 deletions (mean 4.5%, s.d. 2.0%) and 4.4% for monosomy 17 (mean 1.7%, s.d. 0.9%), respectively. Therefore, both patients with MGUS and 11 patients with bone marrow plasma cell contents below 10% had to be considered as non-evaluable. Both 1p36 and 17p13 deletions were found almost exclusively in patients suffering from advanced disease, ie PCL or myeloma stage III (6/6 1p36 deletions vs 7/8 17p13 deletions). While none of the patients with newly diagnosed MM or PCL had a deletion of the microsatellite D1Z2 at chromosomal region 1p36.3, p53 deletions at 17p13 could be detected in 21% (3/14) of patients at initial diagnosis (Table 3) .
Discussion
The tumor suppressor gene p53 has recently been suggested to belong to a family of structurally and functional related genes including various splicing variants. p73, the first of the new whereas p53 deletions or mutations have rarely been found. 49, 50 Since structural and functional similarities between p53 and p73 have been described, one may hypothesize that p73 acts as a tumor suppressor gene especially in neoplasias lacking p53 abnormalities.
In this study, we first present evidence arguing against a major role of p73 as a tumor suppressor gene in MM development. The importance of p73 alterations in human malignancies has been controversely discussed so far. Several groups have analyzed p73 gene alterations as well as the expression status of the p73 protein in various tumor cell lines and primary cells of different solid tumors. However, consistent with our observations in monoclonal plasma cell disorders, no deletions or mutations of the p73 gene which would support the role of p73 as a tumor suppressor gene have been reported so far. 14, 15, [18] [19] [20] 51 Importantly, even in neuroblastomas, recent data on p73 deletion, mutation, and expression argue that p73 is unlikely to be a tumor suppressor gene inactivated during neuroblastoma development. 52 Second, we present data showing that p53 deletions also occur only in a minority of MM patients. As observed with p73 deletions, the presence of p53 deletions was associated with stage III disease. However, while none of the patients with PCL had a 1p36.3 deletion, two out of four patients with PCL had a p53 deletion. These findings are in agreement with other studies, demonstrating that loss of p53 alleles and somatic mutations of p53 exons 5 to 9 have only been found at a low frequency in MM. 5, 49, 50, 53, 54 Also, p53 alterations are rare in other hematological malignancies like low-grade nonHodgkin's lymphomas or chronic myelogenous leukemia and occur predominantly in advanced disease stages. 2, 4 In contrast, a single recent study described p53 deletions in almost one third of all MM patients at initial diagnosis and even in 54.5% of patients with relapsed MM as evaluated by FISH. 40 However, since 65.2% of the patients analyzed by Drach et al 40 but 73% of the patients in our study had stage III disease, the different frequencies of p53 deletions might be explained by the differences in stage or age distribution of patient samples analyzed. In his patient group, 72% of patients were older than 60 years in contrast to 27 out of 74 or 26 out of 61 evaluable patients in our study (36 or 43%, respectively) . Moreover, most of our patient samples were taken during treatment, where Drach et al did not find any p53 deletions in a limited number of samples investigated.
The findings reported here demonstrate for the first time that p73 deletions are, analogous to p53 deletions, rare in MM. As with other neoplastic disorders, these findings argue against a major role of p73 as a tumor suppressor gene in MM development in a classic Knudson's manner despite known alterations of chromosomal region 1p36 in this disorder. However, also in analogy to other hematological malignancies, rare deletions of p53 as well as p73 seem to be associated with advanced disease stages in MM. Since some studies have indicated that aberrant p73 gene expression levels might play a role in tumor growth or progression, 55 mutational as well as expression analyses of the p73 gene in MM samples are under way to elucidate a possible role of gene silencing and mutation in the pathogenesis of MM.
